Loading publications…
The last 5 uploaded publications
Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years
Rajiv Khanna, George Ambalathingal, Nada Hamad, Joe Sasadeusz, Rebecca Pearson, Chien‐Li Holmes‐Liew, Deepak Singhal, Matthew Tunbridge, Wei Yang Ng, Kirsty Sharplin, Andrew S. Moore, David Deambrosis, Trisha Soosay Raj, Peter McNaughton, Morag Whyte, Chris Fraser, Andrew Grigg, David Kliman, Ashish Bajel, Katherine D. Cummins, Mark R. Dowling, Zhi Han Yeoh, Simon J. Harrison, Amit Khot, Sarah Tan, Izanne Roos, Ray Mun Koo, S. Döhrmann, David Ritchie, Brynn Wainstein, Karen McCleary, Adam Nelson, Bradley J. Gardiner, Shafqat Inam, Xavier C. Badoux, Kris Pui Kwan, Claudia Toro, Diane Hanna, David J. Hughes, Rachel Conyers, Theresa Cole, Stacie Shiqi Wang, Lynette Chee, Jacqueline Fleming, Ashley Irish, Duncan Purtill, Peter J. Shaw, Julian Cooney, Siok‐Keen Tey, Stewart Hunt, Elango Subramoniapillai, George John, Michelle Ng, Shanti Ramachandran, Peter Hopkins, Daniel C. Chambers, Scott B. Campbell, Ross S. Francis, Nicole Isbel, Paula Marlton, Michelle A. Neller, Hilary Reddiex, Katherine Matthews, Meggie Voogt, Archana Panikkar, Leone Beagley, Sweera Rehan, Shannon E. Best, Jyothy Raju, Laëtitia Le Texier, Pauline Crooks, Matthew D. Solomon, Lea Lekieffre, Sriganesh Srihari Srih, Corey Smith (2024). Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years. , DOI: https://doi.org/10.21203/rs.3.rs-4511207/v1.
Preprint63 days agoCompassionate access to virus-specific T cells for adoptive immunotherapy over 15 years
Michelle A. Neller, George Ambalathingal, Nada Hamad, Joe Sasadeusz, Rebecca Pearson, Chien‐Li Holmes‐Liew, Deepak Singhal, Matthew Tunbridge, Wei Yang Ng, Kirsty Sharplin, Andrew S. Moore, David Deambrosis, Trisha Soosay Raj, Peter McNaughton, Morag Whyte, Chris Fraser, Andrew Grigg, David Kliman, Ashish Bajel, Katherine D. Cummins, Mark R. Dowling, Zhi Han Yeoh, Simon J. Harrison, Amit Khot, Sarah Tan, Izanne Roos, Ray Mun Koo, S. Döhrmann, David Ritchie, Brynn Wainstein, Karen McCleary, Adam Nelson, Bradley J. Gardiner, Shafqat Inam, Xavier C. Badoux, Kris Pui Kwan, Claudia Toro, Diane Hanna, David J. Hughes, Rachel Conyers, Theresa Cole, Stacie Shiqi Wang, Lynette Chee, Jacqueline Fleming, Ashley Irish, Duncan Purtill, Julian Cooney, Peter J. Shaw, Siok‐Keen Tey, Stewart Hunt, Elango Pillai, George John, Michelle Ng, Shanti Ramachandran, Peter Hopkins, Daniel C. Chambers, Scott B. Campbell, Ross S. Francis, Nicole Isbel, Paula Marlton, Hilary Reddiex, Katherine Matthews, Meggie Voogt, Archana Panikkar, Leone Beagley, Sweera Rehan, Shannon E. Best, Jyothy Raju, Laëtitia Le Texier, Pauline Crooks, Matthew D. Solomon, Lea Lekieffre, Sriganesh Srihari, Corey Smith, Rajiv Khanna (2024). Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years. , 15(1), DOI: https://doi.org/10.1038/s41467-024-54595-2.
Article63 days agoCAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study
Adrian Minson, Nada Hamad, Chan Y. Cheah, Constantine S. Tam, Piers Blombery, David Westerman, David Ritchie, Huw Morgan, Nicholas Holzwart, Stephen Lade, Mary Ann Anderson, Amit Khot, John F. Seymour, Molly Robertson, Imogen Caldwell, Georgina L. Ryland, Javad Saghebi, Zahra Sabahi, Jing Xie, Rachel Koldej, Michael Dickinson (2023). CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study. , 143(8), DOI: https://doi.org/10.1182/blood.2023021306.
Article63 days agoTime-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with <i>TP53</i> Mutated and Btki-Refractory Disease: First Report of the Tarmac Study
Adrian Minson, Nada Hamad, Chan Y. Cheah, Constantine S. Tam, Piers Blombery, David Westerman, Stephen Lade, David Ritchie, Rachel Koldej, Mary Ann Anderson, Amit Khot, John F. Seymour, Molly Robertson, Imogen Caldwell, Georgina L. Ryland, Jing Xie, Huw Morgan, Michael Dickinson (2022). Time-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with <i>TP53</i> Mutated and Btki-Refractory Disease: First Report of the Tarmac Study. , 140(Supplement 1), DOI: https://doi.org/10.1182/blood-2022-160459.
Article63 days agoAllogeneic Haematopoietic Cell Transplantation for Mantle Cell Lymphoma Can Achieve Durable Remission and Myeloablative Conditioning Is Associated with Inferior Survival: An Australasian Bone Marrow Transplant Recipient Registry Study
Pietro R Di Ciaccio, David Ritchie, Glen Kennedy, Samuel T. Milliken, Duncan Purtill, David Gottlieb, Travis Perera, David T Yeung, Stephen Larsen, Richard Doocey, Matthew Greenwood, Simon Durrant, Anne-Marie Watson, Andrew Butler, Amit Khot, Cameron Curley, Nada Hamad (2021). Allogeneic Haematopoietic Cell Transplantation for Mantle Cell Lymphoma Can Achieve Durable Remission and Myeloablative Conditioning Is Associated with Inferior Survival: An Australasian Bone Marrow Transplant Recipient Registry Study. , 27(3), DOI: https://doi.org/10.1016/s2666-6367(21)00509-1.
Article63 days ago